[Challenges in prostate biopsies : From the perspective of practicing urologists and professional policy perspective]

Prostate biopsy is a core area of urology and a central component in the detection of the most common cancer in older men. Increasing demands on hygiene and quality of diagnostics have not been adjusted in the current reimbursement system for outpatient provision in the SHI (statutory health insurance) system.

Presentation of the current situation regarding prostate biopsy; discussion about the further feasibility in the outpatient setting. Professional political assessment and creation of a list of demands for economic coverage of the cost associated with prostate biopsies in the SHI system.

Discussion of basic work and negotiations with the KBV ("Kassenärztliche Bundesvereinigung") using the current valid S3 guideline prostate cancer. Assessment of federal billing modalities of the SHI system.

Costs associated with prostate biopsies are not adequately covered under the current outpatient billing options, considering the steadily increasing demands on the quality of diagnostics as specified in the S3 guideline for prostate cancer, and the required hygiene levels; thus, a two-class medical system is encouraged by self-pay services for improved diagnostics.

Urology specialists are encouraged to find solutions. Prostate biopsy must be considered as an outpatient operation and financed accordingly.